Yan Leyfman: Managing Infection Risk in Myeloma – Time to Rethink IgRT?
Yan Leyfman, Medical Correspondent at OncLive, shared on LinkedIn about a recent paper by Rahul Banerjee et al. published in American Society of Hematology:
“Managing Infection Risk in Myeloma: Time to Rethink IgRT?
Bispecific antibodies (bsAbs) like teclistamab, elranatamab, talquetamab, and linvoseltamab are transforming multiple myeloma treatment—but bring a persistent risk of infection.
Enter immunoglobulin replacement therapy (IgRT) – via IVIG or SCIG – as a key prevention strategy. But should it be preemptive or prophylactic?
In this Viewpoint, led by Dr. Rahul Banerjee of Fred Hutchinson Cancer Research, the authors argue for primary IgRT prophylaxis:
- Safer
- Simpler
- More clinically sound than relying on arbitrary IgG thresholds
They also outline strategies to improve IgRT access and cost-effectiveness globally – advocating for proactive care in the bsAb era.”
Title: IVIG prophylaxis should be initiated following bispecific antibody therapy in multiple myeloma regardless of IgG levels
Authors: Rahul Banerjee, Meera Mohan, Kai Rejeski, Benjamin R. Puliafito, Diana D. Cirstea, Gurbakhash Kaur, Shonali Midha, Georgia J McCaughan, Nikhil M Kumar, Nikita Mehra, Bhausaheb Bagal, Noopur S. Raje
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023